BioTuesdays

Author - Leonard Zehr

Cellect Biotechnology
Developments

Cellect completes NASDAQ IPO

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary...

August 3, 2016
Keryx Biopharmaceuticals Logo
Markets

Stifel downgrades Keryx to hold

Stifel downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target after the company announced an imminent supply disruption with its Auryxia product. The stock closed at $4.72 on...

August 2, 2016
Medical Facilities
Markets

Echelon starts Medical Facilities at buy

Echelon Wealth Partners initiated coverage of Medical Facilities (TSX:DR) with a “buy” rating and one-year price target of $22.50. The stock closed at $21.50 on Monday. Medical Facilities (MFC) is a physician-owned...

August 2, 2016
oramed
Developments

Oramed gets additional milestone from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China. The milestone is part of a license and investment agreement between...

August 2, 2016
Sucampo Pharmaceuticals
Markets

Maxim cuts Sucampo Pharma price target to $17

Maxim Group lowered its price target for Sucampo Pharmaceuticals (NASDAQ:SCMP) to $17 from $26, citing a combination of the market environment and an assessment of the catalysts and risks. The stock was quoted at $11.89...

August 1, 2016
Galmed Logo
Markets

Maxim cuts Galmed Pharma price target to $9

Maxim Group lowered its price target for Galmed Pharmaceuticals (NASDAQ:GLMD) to $9 from $24, citing a bearish biotech market environment, catalysts, and revisions to timelines, as well as other related assumptions. The...

August 1, 2016
Seres Therapeutics Logo
Markets

HCW cuts Seres Therapeutics price target to $15

H.C. Wainwright lowered its price target for Seres Therapeutics (NASDAQ:MCRB) to $15 from $50 after disappointing Phase 2 results in patients with recurrent C. difficile infection (CDI). The stock was quoted at $9.83...

August 1, 2016
Spartan Bioscience Logo
Developments

Spartan announces first applications for Cube

Closely-held Spartan Bioscience has launched the world’s smallest commercial molecular diagnostic device, the Spartan Cube, and announced its first assay applications. They are Strep A, Apolipoprotein E, a genetic...

August 1, 2016
Stellar Biotechnologies
Markets

Maxim cuts Stellar Biotechnologies price target to $7

Maxim Group lowered its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $7 from $17, citing market environment, catalysts related to clients for Stellar’s Keyhole Limpet Hemocyanin (KLH) protein, revisions to...

August 1, 2016